CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 170 filers reported holding CLOVIS ONCOLOGY INC in Q4 2018. The put-call ratio across all filers is 0.47 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $106,000 | -53.3% | 15,062 | -68.2% | 0.00% | – |
Q4 2020 | $227,000 | -16.8% | 47,299 | +0.9% | 0.00% | – |
Q3 2020 | $273,000 | -13.6% | 46,889 | +0.0% | 0.00% | – |
Q2 2020 | $316,000 | +6.0% | 46,878 | +0.1% | 0.00% | – |
Q1 2020 | $298,000 | -64.7% | 46,811 | -42.3% | 0.00% | -100.0% |
Q4 2019 | $845,000 | +78.6% | 81,089 | -32.6% | 0.00% | 0.0% |
Q3 2019 | $473,000 | -73.6% | 120,276 | 0.0% | 0.00% | -50.0% |
Q2 2019 | $1,789,000 | -29.7% | 120,276 | +1.1% | 0.00% | 0.0% |
Q1 2019 | $2,545,000 | +138.5% | 118,982 | +100.2% | 0.00% | +100.0% |
Q4 2018 | $1,067,000 | -38.9% | 59,431 | 0.0% | 0.00% | -50.0% |
Q3 2018 | $1,745,000 | -34.2% | 59,431 | +1.9% | 0.00% | -33.3% |
Q2 2018 | $2,651,000 | +4.7% | 58,306 | +21.6% | 0.00% | 0.0% |
Q1 2018 | $2,532,000 | -22.4% | 47,961 | 0.0% | 0.00% | -25.0% |
Q4 2017 | $3,261,000 | +48.6% | 47,961 | +80.1% | 0.00% | +33.3% |
Q3 2017 | $2,195,000 | – | 26,633 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |